Recipharm's Arranta Bio expands RNA process development capacity by 50 percent to meet increased customer demand
Arranta Bio, a Recipharm company and leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, has announced that it has doubled capacity at its Watertown, MA facility for process development services supporting RNA therapeutics. This major development comes less than a year after the acquisition of Arranta Bio by Recipharm, demonstrating Recipharm’s continued focus on the advanced therapeutics market. The expansion includes the fit out of approximately 2,000 ft2 of state-of-the-art laboratory space with flexible, modular small scale and pilot scale equipment to enable rapid development and scale up to GMP manufacturing.
The Watertown facility is an 80,000 ft2 commercial-ready GMP manufacturing facility with Grade C production suites suitable for the end-to-end production of mRNA, lipid nanoparticle formulation, and automated sterile fill finish into vials or syringes within a gloveless, robotic isolator. The facility has capabilities for process and analytical development and GMP manufacturing for drug substance and drug product.
David Stevens, CEO of Arranta Bio, said: “The opening of our additional development laboratory space for RNA technologies at Watertown means we are well positioned to help our clients quickly and effectively scale up processes for successful GMP manufacturing. Arranta’s ability to support best-in-class process development prior to GMP is critically important in achieving the objective of reducing the amount of time to get into the clinic and successfully advancing life-changing medicine to patients.”
Led by a highly experienced and expert team, Arranta continues to invest in expanding and enhancing its capabilities and commercial-ready facilities. Arranta is proud to be a leading CDMO focused on supporting the development and GMP supply needs of advanced therapeutics innovator companies.
Recipharm completed the acquisition of Arranta in April 2022, building on its presence in the biologics market, with a particular focus on drug substance manufacturing of novel ATMPs.
For media enquiries, please contact fiona.whyatt@
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm and our services, please visit www.recipharm.com
About Arranta Bio
Founded in 2019, Arranta Bio is a visionary contract development and manufacturing organization (CDMO) that partners with companies seeking to develop and manufacture complex biological drugs and innovative therapies. Our dedicated team, state-of-the-art facilities, and unparalleled resources are crucial for advancing products from development to commercial launch. Arranta Bio continues to expand capacity and development and manufacturing services across multiple sites with technology platforms designed to meet the evolving demands of our clients and partners.
For more information, please visit www.arrantabio.com